Investigational direct-acting antivirals in hepatitis C treatment: The latest drugs in clinical development

Expert Opinion on Investigational Drugs

Volumn 25, Issue 5, 2016, Pages 557-572

  Gentile, Ivan ^a   Scotto, Riccardo ^a   Zappulo, Emanuela ^a   Buonomo, Antonio Riccardo ^a   Pinchera, Biagio ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cirrhosis; elbasvir; grazoprevir; HCV; resistance; sofosbuvir; velpatasvir

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DELEOBUVIR; ELBASVIR; FALDAPREVIR; GRAZOPREVIR; INTERFERON; NONSTRUCTURAL PROTEIN 5A INHIBITOR; ODALASVIR; PEGINTERFERON; RAVIDASVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VELPATASVIR; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; BENZAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; MK-5172; NEW DRUG; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CROSS RESISTANCE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; IC50; KIDNEY FUNCTION; LIVER CIRRHOSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT FAILURE; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; BENZAZEPINES; BENZOFURANS; DRUGS, INVESTIGATIONAL; HEPATITIS C; HUMANS; IMIDAZOLES; INDOLES; ISOQUINOLINES; QUINOXALINES; SOFOSBUVIR; SULFONAMIDES;

EID: 84961391454     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1161023     Document Type: Review

References (106)

1. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide-filling the gaps. J Viral Hepat. 2015; 22 (Suppl 1): 1-5.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol. 2013; 57: 1333-1342.
3. Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic hepatitis C. Hepat Mon. 2013; 13: e8352.
4. Sagnelli E, Pisaturo M, Stanzione M, et al. Presentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol. 2013; 13: 00466-7.
5. Coppola N, Zampino R, Bellini G, et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013; 21: 00687-3.
6. Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo. 2013; 27: 773-777.
7. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012; 26: 401-412.
8. Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol. 2014; 13: 20-26.
9. Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol. 2009; 43: 81-87.
10. Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem. 2001; 47: 1696-1700.
11. Zampino R, Pisaturo MA, Cirillo G, et al. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol. 2015; 14: 75-82.
12. Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol. 2013; 65: 83-84.
13. Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis. 2014; 33: 559-567.
14. Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol. 2010; 52: 778.
15. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360: 1827-1838.
16. Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1195-1206.
17. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1207-1217.
18. Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem. 2006; 49: 6074-6086.
19. Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 2006; 70: 28-38.
20. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006; 6: 3-16.
21. Borgia G, Reynaud L, Gentile I, et al. Case report: pernicious anemia during IFN- treatment for chronic hepatitis C. J Interferon Cytokine Res. 2003; 23: 11-12.
22. Borgia G, Reynaud L, Gentile I, et al. Myasthenia gravis during low-dose IFN- therapy for chronic hepatitis C. J Interferon Cytokine Res. 2001; 21: 469-470.
23. Gentile I, Viola C, Reynaud L, et al. Case report: hemolytic anemia during pegylated IFN-2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res. 2005; 25: 283-285.
24. Tosone G, Borgia G, Gentile I, et al. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol. 2007; 44: 167-169.
25. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol. 2013; 59: 434-441.
26. DAmbrosio R, Colombo M. Safety of direct antiviral agents in real life. Dig Liver Dis. 2013; 30: 012.
27. De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 2014; 89: 441-452.
28. Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs. 2014; 23: 561-571.
29. Gentile I, Buonomo AR, Borgia F, et al. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014; 23: 719-728.
30. Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014; 23: 1211-1223.
31. Gentile I, Buonomo AR, Zappulo E, et al. Discontinued drugs in 2012.-2013: hepatitis C virus infection. Expert Opin Investig Drugs. 2015; 24: 239-251.
32. Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther. 2014; 12: 763-773.
33. Gentile I, Borgia G., A pill a day keeps HCV away. Lancet Infect Dis. 2015; 15: 616-617.
34. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368: 34-44.
35. Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem. 2014; 21: 1391-1404.
36. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013; 28: 38-45.
37. Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 2013; 7: 105-115.
38. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014; 59: 1666-1674.
39. Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012; 57: 24-31.
40. Mogalian E, Mathias A, Brainard D, et al. P0712: the pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. J Hepatol. 2015; 62: SS590-1.
41. Mogalian E, Mathias A, Brainard D, et al. P742 the pharmacokinetics of VEL, a pan-genotypic HCV Ns5a inhibitor, in HCV-uninfected subjects with moderate and severe hepatic impairment. J Hepatol. 2014; 60: S317.
42. Gilead, Sciences. Press release: Gilead announces phase 2 results for two investigational all-oral sofosbuvir-based regimens for the treatment of chronic hepatitis C; 2014 [. cited 2015 Nov 13[. Available from: http://www.gilead.com/news/press-releases/2014/4/gilead-announces-phase-2-results-for-two-investigational-alloral-sofosbuvirbased-regimens-for-the-treatment-of-chronic-hepatitis-c
43. Gilead, Sciences. Press release: gilead announces phase 2 data for investigational all-oral regimen of sofosbuvir plus GS-5816 for the treatment of chronic hepatitis C; 2014 [. cited 2015 Nov 13[. Available from: http://www.gilead.com/news/press-releases/2014/11/gilead-announces-phase-2-data-for-investigational-alloral-regimen-of-sofosbuvir-plus-gs5816-for-the-treatment-of-chronic-hepatitis-c#sthash.fvUszI56.dpuf
44. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015; 373: 2599-2607.
45. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015; 373: 2608-2617.
46. Curry MP, OLeary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015; 373: 2618-2628.
47. Gilead, Sciences. Report: gilead announces data for investigational, All-oral, pan-genotypic three-drug regimen of sofosbuvir, VEL and GS-9857 for chronic hepatitis C; 2015 [. cited 2015 No v 13[. Available from: http://phx.corporate-ir.net/External.File?t=2&item=g7rqBLVLuv81UAmrh20MpywheWEscWlCEvwH.
48. Gilead, Sciences.; 2015 [. cited 2015 Nov 13[. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02536313
49. Yang G, Wiles J, Patel D, et al. 845 preclinical characteristics of ach-3102: a novel HCV Ns5a inhibitor with improved potency against genotype-1a virus and variants resistant to 1St generation of Ns5a inhibitors. European association for the study of the liver. J Hepatol. 2012; 56: S330.
50. Muir AHJ, Hill J, Lawitz E, et al. 876 ACH-3102, a second generation NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1a HCV infection despite the presence of baseline NS5A-resistant variants. J Hepatol. 2013; 58: S360.
51. Gane E, Schwabe C, Mader M, et al. LP06: sustained virologic response after ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: a phase 2 "proxy" study. Elsevier. J Hepatol. 2015; 62: S266.
52. Patel D, Zhao Y, Fabrycki J, et al. P0805: achievement of SVR12 despite the presence of HCV variants resistant to first generation NS5A inhibitors in genotype-1 hepatitis C patients after 8-week therapy of ACH-3102 in combination with sofosbuvir. Elsevier. J Hepatol. 2015; 62: S636.
53. Esmat G, El Raziky M, Gomaa A, et al. High virologic response rate in Egyptian HCV-genotype 4 patients treated with ravidasvir (PPI-668) and sofosbuvir: results of a large multicenter phase 3 registrational trial. In: Annual Meeting of the American Association for the study of liver diseases. San Francisco (CA); 2015. [cited 2016 Mar 14]. Available from: http://www.natap.org/2016/CROI/croi-101.htm
54. Lalezar JP, Holland L, Glutzer E, et al. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir, and PPI-668, with and without ribavirin, in patients with HCV genotype-1a infection. AASLD Oral Presentation. Hepatol. 2013; 58: 36A-91A. Oral LB-20.
55. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012; 56: 5387-5396.
56. Soumana DI, Ali A, Schiffer CA. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol. 2014; 9: 2485-2490.
57. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatol. 2012; 55: 742-748.
58. Mosure KW, Knipe JO, Browning M, et al. Preclinical pharmacokinetics and in vitro metabolism of asunaprevir (BMS-650032), a potent hepatitis C virus NS3 protease inhibitor. J Pharm Sci. 2015; 104: 2813-2823.
59. Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2015; 20: 29-37.
60. Garimella T, He B, Luo W-L, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. Hepatol. 2013; 58: 430A-A.
61. Pasquinelli C, McPhee F, Eley T, et al. Single-and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012; 56: 1838-1844.
62. Bronowicki J-P, Pol S, Thuluvath PJ, et al. Randomized study of asunaprevir plus pegylated interferon- and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther. 2013; 18: 885-893.
63. Bronowicki J-P, Ratziu V, Gadano A, et al. 1420 asunaprevir with peginterferon-alfa and ribavirin in treatment-naive patients with genotype-1 OR-4 chronic hepatitis C: SVR24 results from a randomized phase 2B study (AI447016). J Hepatol. 2013; 58: SS571-SS572.
64. Vierling JM, Lataillade M, Gane EJ, et al. Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study. Hepatol. 2012; 56: 1522-1523.
65. Jensen D, Sherman KE, Hezode C, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015; 63: 30-37.
66. Piroth L, Paniez H, Taburet AM, et al. High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced, null-responder patients with HIV/hepatitis C virus genotype 1/4 coinfection: the ANRS HC30 QUADRIH study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Clin Infect Dis. 2015; 61: 817-825.
67. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366: 216-224.
68. Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014; 60: 490-499.
69. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013; 58: 655-662.
70. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatol. 2014; 6: 27113.
71. Manns M, Pol S, Jacobson I. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1B infection: phase 3 study results. J Hepatol. 2014; 60: S524-S5.
72. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384: 1597-1605.
73. Nakamuta M, Kohjima M, Motomura K, et al. Early HCV kinetics during dual oral therapy with daclatasvir and asunaprevir. J Hepatol. Vienna; 2015; 62: S648-S649.
74. Lemm JA, Liu M, Gentles RG, et al. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2014; 58: 3485-3495.
75. Liu M, Tuttle M, Gao M, et al. Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes. Antimicrob Agents Chemother. 2014; 58: 7416-7423.
76. Sims KD, Lemm J, Eley T, et al. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrob Agents Chemother. 2014; 58: 3496-3503.
77. Tatum H, Thuluvath PJ, Lawitz E, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015; 22: 658-664.
78. Tatum H, Thuluvath P, Lawitz E, et al. Safety and efficacy of BMS-791325, a non-nucleoside NS5B polymerase inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive patients infected with hepatitis C virus genotype 1. AASLD Poster. Hepatol. 2013;58: 141A. P1126.
79. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterol. 2014; 146: 420-429.
80. Everson G, Sims KD, Thuluvath PJ, et al. Daclatasvir in combination with asunaprevir and beclabuvir for prior null responders with chronic HCV genotype 1 infection. AASLD Poster. Hepatology. 2014; 60:188A. P1943.
81. Everson G, Sims KD, Thuluvath PJ, et al. Daclatasvir in combination with asunaprevir and beclabuvir for prior null responders with chronic HCV genotype 1 infection. Poster presented at:. The Liver Meeting® 2014, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2014 Nov 7-11; Boston (MA). Poster 1943.
82. Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015; 62: 1204-1206.
83. Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA: J Am Med Assoc. 2015; 313: 1728-1735.
84. Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA: J Am Med Assoc. 2015; 313: 1736-1744.
85. Everson GT, Sims KD, Thuluvath PJ, et al. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016; 36: 189-197.
86. Adamczyk R, Sims K, Hesney M. The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir. J Hepatol. 2015; 62: S628. P0790.
87. Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012; 56: 4161-4167.
88. Harper S, McCauley JA, Rudd MT, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett. 2012; 3: 332-336.
89. Manns MP, Vierling JM, Bacon BR, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterol. 2014; 147: 366-76.e6.
90. Lagging M, Brown A, Mantry PS, et al. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepa. 2016; 23: 80-88.
91. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385: 1087-1097.
92. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385: 1075-1086.
93. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 Infection after failure of pegylated interferon and ribavirin with an earlier-genera-tion protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016; 62: 32-36.
94. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163: 1-13.
95. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386: 1537-1545.
96. Yee BE, Nguyen NH, Zhang B, et al. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. BMJ Open Gastroenterol. 2015; 2: e000049.
97. Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011; 8: 212-223.
98. Vierling JM, Zeuzem S, Poordad F, et al. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014; 61: 200-209.
99. Yang D, Liang HJ, Li D, et al. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials. Intern Med. 2013; 52: 653-660.
100. Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir-a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs. 2010; 19: 151-159.
101. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013; 57: 221-229.
102. Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase IIb/III studies. J Hepatol. 2015; 62: 1008-1014.
103. Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013; 444: 329-336.
104. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir RBV. Hepatol. 2014; 60: 1128A.
105. Poordad F, Sievert W, Mollison L. All-oral, fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 phase 3 SVR12 results. Poster presented at The Liver Meeting 2014, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2014 Nov 7-11; Boston (MA). Poster LB-7.
106. Muir A, Poordad F, Lalezari J, et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir, ± ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results. AASLD Oral presentation. Hepatol. 2014; 60: 32A-91A.Oral LB-2.